

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
34633	12/WN/0341	A double-blind, randomised, placebo-controlled, multicentre study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardio	Available	22	Available	42071	Open	N/A	
34634	13/NW/0054	A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis	Available	20	Available	41718	Closed - Follow Up Complete	Y	
34635	11/SC/0372	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy	Available	5	Available	41734	Withdrawn	N/A	Abandoned- not recruited - we did come in very late to this study with a short recruitment period, which was further reduced with little notice.
34636	13/NI/0044	A study to measure Serum Periostin, asthma-related biomarkers and response to Prednisolone in adult and adolescent patients with severe oral corticosteroid-dependent asthma.	Available	9	Available	41562	Closed - Follow Up Complete	N	
34637	13/NW/0215	A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-positive, Non-Small Cell Lung Cancer (PEARL-PRAME)	Available	4	Available	41852	Closed - Follow Up Complete	Y	closed early (august 2014)
34638	13/LO/0501	A Phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of Maribavir versus Valganciclovir for the treatment of CMV infections in transplant recipients who do not have cmv organ disease. Maribavir Study.	Available	10	Available	41684	Closed - Follow Up Complete	N	original recruitment period was june 2014 this was cut short
34639	13/WN/0234	A prospective, Multicentre, Controlled Study of Implant-based breast reconstruction, measuring the safety, effectiveness and cost consequences, of Immediate Single Stage Breast Reconstruction with Stratice Reconstructive Tissue Matrix versus Immediate Two	Available	10	Available	41827	Closed - Follow Up Complete	Y	
34640	13/NW/0462	Randomised, double-blind, dose-finding Phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplatin - or anthracycline / Cyclophosphamide (AC)-based chemotherapy	Available	10	Available	41944	Open	Y	
34641	13/EM/0230	A Phase II Randomised, Double-Blind, Placebo-Controlled, Multicenter study of VS6063 in subjects with Malignant Pleural Mesothelioma	Available	10	Available	42064	Open	Y	
34642	13/NW/0586	A study to Assess RepeatTreatment Efficacy and Safety of Rifaximin 550mg TID in Subjects with irritable Bowel Syndrome with Diarrhoea (IBS-D)	Available	40	Available	42368	Closed - Follow Up Complete	N	
34643	13/YH/0232	A randomised double-blind (sponsor-unblind) placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics of inhaled GSK2339345 in patients with chronic idiopathic cough using an aqueous droplet inhaler. Echo	Available	10	Available	41869	Closed - In Follow Up	Y	original target was 20 patients, this target was reduced to 10 during the study
34644	13/SC/0348	A randomised, open label Phase II study evaluating LY2875358 plus Erlotinib and LY2875358 monotherapy in MET diagnostic positive NSCLC patients with acquired resistance to Erlotinib	Available	1	Available	41852	Closed - Follow Up Complete	N	closed early in august 2014
34645	13/LO/0219	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)	Available	3	Available	42109	Open	N/A	july 2014 was the original date for end of recruitment this has been extended and we are still open to recruitment
34646	13/LO/1121	A randomized, controlled phase 2 study evaluating LY2875358 plus Erlotinib versus Erlotinib as first-line treatment in Metastatic non-small cell lung cancer patients with activating EGFR mutations who have disease control after 8-week lead-in treatment with Erlotinib	Available	6	Available	41944	Open	N/A	
34647	13/NE/0094	Phased RF Evaluation of Acute Pulmonary Vein Isolation in Paroxysmal AF with new GENIUS UI and PVAC GOLD.	Available	10	Available	41791	Closed - In Follow Up	N	original recruitment date july 2014
34648	13/NW/0283	GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual anti-platelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and Biomatrix family drug-eluting stent use.	Available	150	Available	42156	Open	N/A	
34649	13/LO/1348	Lutonix	Available	13	Available	41851	Closed - In Follow Up	Y	original target was 20-24 with an end of recruitment date of 1/6/15 the target and end of recruitment date was reduced
34650	13/NI/04148	A phase II, randomised, double-blind, placebo-controlled, multicentre trial to assess the oral corticosteroid-sparing effect of lebrikizumab in patients with severe corticosteroid-dependent asthma - VOCALS	Available	12	Available	42005	Open	Y	
34651	13/WN/0235	Atrial Fibrillation Progression Trial (ATTEST Trial)	Available	5	Available	42064	Open	N/A	
34652	13/NW/0583	A 24 Week International, Multi-center, Randomised, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise	Available	5	Available	42064	Open	N/A	
34653	13/SS/0044	Efficacy and safety of lidocaine 5% medicated plaster in localised chronic post-operative neuropathic pain	Available	6	Available	42004	Open	N/A	
34654	13/SC/0384	A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma	Available	10	Available	41944	Open	Y	
34655	13/YH/0282	Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous (SC) Tocilizumab monotherapy or combination therapy with methotrexate (MTX) or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with severe Rheumatoid Arthritis (RA) who are being treated with an anti-tumour necrosis factor (anti-TNF) agent and that have not achieved an adequate response to treatment	Available	5	Available	42186	Open	N/A	
34656	13/EE/0326	REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PALCEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS	Available	48	Available	42217	Open	N/A	
34657	13/NW/0612	Benralizumab treatment in patients with uncontrolled asthma (SIROCCO)	Available	1	Available	42513	Open	Y	
34658	13/WA/0084	CV Outcomes following Treatment with MK3102 in Subjects with T2DM	Available	7	Available	01/10/2014	Closed - In Follow Up	N	original date agreed to recruit target number of patients cut short
34659	13/SC/0312	SEE - HF Study	Available	25	Available	01/03/2015	Open	N/A	
34660	12/EM/0284	A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial.	Available	3	Available	18/02/2013	Closed - In Follow Up	N	
34661	14/ES/0001	Ertugliflozin in participants with T2DM & Vascular disease	Available	11	Available	01/06/2015	Open	N/A	
34662	13/LO/0867	1199.93 - Nintedanib in Mesothelioma	Available	4	Available	01/12/2014	Open	Y	
34663	14/EM/0024	A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active Psoriatic Arthritis	Available	3	Available	22/09/2014	Open	Y	

34664	14/NE/0016	IRIS-3: A 12 week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral lisdexamfetamine 10mg once daily in female patients with Irritable Bowel Syndrome with Diarrhoea (IBS-D)	Available	10	Available	01/09/2015	Open	N/A	
34665	14/NW/0211	A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic idiopathic cough.	Available	10	Available	01/03/2015	Open	N/A	
34666	13/LO/0184	Prevention of Thromboembolic Events - European Registry in Venous Thromboembolism - PREFER in VTE	Available	20	Available	18/07/2014	Closed - Follow Up Complete	Y	
34667	13/SW/0236	Post-Authorisation Safety Study (PASS) of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting - PASSPORT	Available	10	Available	18/08/2014	Closed - In Follow Up	Y	
37211	14/WS/0004	Open-label Extension Study of EFC12492, R727-CL-1112, EFC12732 & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia	Available	2	Available	01/09/2014	Closed - In Follow Up	Y	
37212	14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	Available	6	Available	30/03/2015	Open	N/A	
37213	14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	Available	2	Available	31/12/2014	Open	N/A	
37214	14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)	Available	4	Available	01/09/2015	Open	N/A	